Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
The Journal of Dermatology, 03/23/2012Igarashi A et al.
Ustekinumab was efficacious and generally well–tolerated in Japanese patients with moderate–to–severe plaque–type psoriasis through 72 weeks. These results are consistent with those reported in the global, phase 3 studies.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.